Ortega, NataliaRibes, MartaVidal, MartaRubio, RocíoAguilar, RuthWilliams, SarahBarrios, DianaAlonso, SelenaHernández-Luis, PabloMitchell, Robert A.Jairoce, ChenjeraiCruz, AngelineJiménez, AlfonsSantano, RebecaMéndez, SusanaLamoglia Puig, MontserratRosell, NeusLlupià García, AnnaPuyol, LauraChi, JordiRodrigo-Melero, NataliaParras, DanielSerra, PauPradenas Saavedra, EdwardsTrinité, BenjaminBlanco, JuliàMayor Aparicio, Alfredo GabrielBarroso, SoniaVarela, PilarVilella, AnnaTrilla Garcia, Antonio De PaduaSantamaria, PereCarolis, CarloTortajada, MartaIzquierdo Lázaro, LuisAngulo Aguado, AnaEngel Rocamora, PabloGarcia-Basteiro, Alberto LMoncunill Piñas, GemmaDobaño, Carlota, 1969-2026-01-142026-01-142021-08-062041-1723https://hdl.handle.net/2445/225440Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.10 p.application/pdfengcc-by (c) Ortega, N. et al., 2021http://creativecommons.org/licenses/by/4.0/SARS-CoV-2Pandèmia de COVID-19, 2020-2023SARS-CoV-2COVID-19 Pandemic, 2020- 2023info:eu-repo/semantics/article7153452026-01-14info:eu-repo/semantics/openAccess34362897